bpc 157 modulates neurotransmitters Stable Gastric Pentadecapeptide as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System Peptide Therapy for Inflammation: A

Description

Analytical testing confirms GHK-Cu 62.1 mg, TB-500 14.96 mg, BPC-157 13.63 mg and KPV 10.09 mg with endotoxin levels below 0.001 EU/mg

How to inject BPC-157 intramuscularly (IM) Alternative method for some situations

Bebu, I., Braffett, B

WADA Prohibition The World Anti-Doping Agency explicitly prohibits AOD-9604 for competitive athletes: Listed under Section S0 (Non-Approved Substances) and S2.2.3 (Growth Hormone Fragments) Prohibited at all times (both in-competition and out-of-competition) No Therapeutic Use Exemptions (TUEs) available Detection methods developed and implemented in anti-doping laboratories worldwide WADAs 2013 statement clarified that AOD-9604 is a substance still under pre-clinical and clinical development and has not been approved for therapeutic use by any government health authority in the world. Research Classification: AOD-9604 is available only for laboratory research use